End of an era for erythropoiesis‐stimulating agents in oncology

Autor:	Shamia Hoque, Michael Dickson, Paul R. Yarnold, Oliver Sartor, Bartlett J. Witherspoon, Benjamin Schooley, Chadi Nabhan, Charles L. Bennett, Brian J. Chen, William J. M. Hrushesky, Y. Tony Yang, Martin W. Schoen, Kevin B. Knopf
Rok vydání:	2020
Předmět:	Adult Male Cancer Research medicine.medical_specialty Anemia medicine.medical_treatment Antineoplastic Agents Medical Oncology 03 medical and health sciences Patient safety 0302 clinical medicine Breast cancer hemic and lymphatic diseases Internal medicine Humans Medicine Dosing Practice Patterns Physicians' Adverse effect Reimbursement Chemotherapy business.industry medicine.disease United States Oncology 030220 oncology & carcinogenesis Hematinics Female business Medicaid
Zdroj:	International Journal of Cancer. 146:2829-2835
ISSN:	1097-0215 0020-7136
DOI:	10.1002/ijc.32917
Popis:	Erythropoiesis-stimulating agents (ESAs) are available to treat chemotherapy-induced anemia (CIA). In 2007-2008, regulatory notifications advised of venous thromboembolism and mortality risks while the Center for Medicare and Medicaid Services' restricted ESA initiation to patients with hemoglobin
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b16c80598f233cab573dcabed1e7160 https://doi.org/10.1002/ijc.32917 Zobrazit plný text záznamu Plný text